Cipla shrugs off weak Q2 outcome

Cipla gained 4.57% to Rs 552.25 at 9:25 IST on BSE, with the stock shrugging off the company's announcement of weak Q2 results.

The result was announced after market hours yesterday, 9 November 2016.

Meanwhile, the S&P BSE Sensex was up 309.64 points or 1.14% at 27,562.17.

On BSE, so far 66,000 shares were traded in the counter as against average daily volume of 1.99 lakh shares in the past one quarter. The stock hit a high of Rs 554.30 and a low of Rs 538 so far during the day.

The large-cap company has equity capital of Rs 160.84 crore. Face value per share is Rs 2.

Cipla said that consolidated net profit dropped 34.75% to Rs 354.34 crore on 8.39% rise in total income to Rs 3778.25 crore in Q2 September 2016 over Q2 September 2015. The company said the results are not strictly comparable to Q2 September 2015 results. The Q2 September 2016 earnings include revenue from InvaGen Pharmaceuticals, a US-based company that Cipla acquired in February this year, and as Q2 September 2015 results included profit from Esomeprazole.

Cipla said that Q2 September 2016 reflected improved profitability in base business driven by better product and geography mix. The company launched 6 new products during this quarter in the US market and continues to invest in building a niche and differentiated product portfolio, Cipla said. Commenting on the results, Umang Vohra, MD and Global CEO, Cipla said that the company continues to stay focused on building operational efficiencies and strengthening presence in priority markets.

Cipla is a global pharmaceutical company

Powered by Capital Market - Live News